Retatrutide Phase 3: What the TRIUMPH Studies Have Reported

The map of the full program, including Phase 1b and Phase 2, is in retatrutide clinical trials. The index is the Retatrutide research hub.

The evidence state in one sentence

Peer-reviewed evidence exists for earlier stages. The TRIUMPH results circulating in 2026 are, in this page’s sources, sponsor topline announcements. Each ClinicalTrials.gov record has its own status.^7,8,1,2

TRIUMPH-1

Registry: NCT05929066. Registry status as reviewed September 1, 2026: Completed. Sponsor topline: May 21, 2026.^3,1

Lilly reported, for the efficacy estimand at 80 weeks and with a mean baseline weight of 112.7 kg, a mean percent body-weight change of −19.0% in the 4 mg arm, −25.9% in the 9 mg arm, −28.3% in the 12 mg arm, and −2.2% with placebo. An estimand is a defined way of answering the trial question; it is not an individual prescription.¹

Lilly also reported that 45.3% of participants in the 12 mg arm reached ≥ 30% weight reduction, and that in a prespecified extension in people with BMI ≥ 35 the 12 mg arm reached a mean change of −30.3% at 104 weeks. Those figures are from the sponsor release.¹

TRIUMPH-2

Registry: NCT05929079. Registry status as reviewed September 1, 2026: Active, not recruiting. Sponsor topline: July 23, 2026. This page does not mark the trial Completed merely because a release exists.^4,2

Lilly reported a trial in adults with obesity or overweight and type 2 diabetes. According to the release, mean percent weight changes at 80 weeks were −12.7% (4 mg study arm), −19.1% (9 mg), and −20.8% (12 mg), with A1C reductions of up to 1.6% on average. Lilly reported those figures; they are not presented here as a Lancet or NEJM paper.²

TRIUMPH-3

Registry: NCT05882045. Registry status as reviewed September 1, 2026: Active, not recruiting. Sponsor topline: July 23, 2026. The same rule: the announcement is not translated into a Completed status.^5,2

Lilly reported a trial in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. According to the release, participants lost up to an average of 22.6% of body weight (55.8 lb) at 80 weeks. That is a sponsor-reported topline result.²

TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 studied different populations. Placing −28.3% next to −20.8% or −22.6% as if the trials were a race is misleading. Each figure belongs to its protocol and its release.

TRIUMPH-Outcomes

Registry: NCT06383390. Registry status as reviewed September 1, 2026: Active, not recruiting. In the reviewed sources there is no completed outcomes result. The registry estimates primary completion in 2029.⁶

What “topline” means

A topline result is an initial summary released by the study sponsor. It may preview primary endpoints and some secondary endpoints. It does not, by itself, include the methods, sensitivity analyses, and limitations that a peer-reviewed paper usually provides.

Lilly stated that detailed TRIUMPH-2 and TRIUMPH-3 results would be presented at medical meetings and published in journals. Until that publication exists, this page does not claim those trials already have a paper comparable to Jastreboff et al. or Rosenstock et al.^2,7,8

What we still need to learn

Still open, among other items, are detailed TRIUMPH publication, additional analyses, regulatory review, and TRIUMPH-Outcomes data. A later paper could specify estimands, per-protocol populations, adverse events, and sensitivity analyses. This page does not speculate on the probability of an approval.

Lilly has stated an intention to submit a U.S. application in the first quarter of 2027. That is a plan. Retatrutide remains an investigational compound and is not currently approved by the FDA. A completed clinical phase or a positive result is not a regulatory authorization.⁹

The FDA page on unapproved GLP-1 drugs refers to the United States and is not translated here into a claim about Mexican law.¹⁰